SG11201810923YA - SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE - Google Patents

SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Info

Publication number
SG11201810923YA
SG11201810923YA SG11201810923YA SG11201810923YA SG11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA SG 11201810923Y A SG11201810923Y A SG 11201810923YA
Authority
SG
Singapore
Prior art keywords
igg
binding peptide
site
labeled antibody
specific radioisotope
Prior art date
Application number
SG11201810923YA
Inventor
Yuji Ito
Yoshinari SHOYAMA
Akio Hayashi
Norihito NAKATA
Original Assignee
Univ Kagoshima
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kagoshima filed Critical Univ Kagoshima
Publication of SG11201810923YA publication Critical patent/SG11201810923YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Abstract

SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc. [Fig. 7]
SG11201810923YA 2016-06-13 2017-06-12 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE SG11201810923YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016117395 2016-06-13
JP2016227025 2016-11-22
PCT/JP2017/021558 WO2017217347A1 (en) 2016-06-13 2017-06-12 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Publications (1)

Publication Number Publication Date
SG11201810923YA true SG11201810923YA (en) 2019-01-30

Family

ID=60663283

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012408UA SG10202012408UA (en) 2016-06-13 2017-06-12 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
SG11201810923YA SG11201810923YA (en) 2016-06-13 2017-06-12 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202012408UA SG10202012408UA (en) 2016-06-13 2017-06-12 SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE

Country Status (8)

Country Link
US (1) US20200181196A1 (en)
EP (1) EP3470418A4 (en)
JP (2) JP6959616B2 (en)
KR (2) KR20190018423A (en)
CN (1) CN109071606A (en)
CA (1) CA3026520A1 (en)
SG (2) SG10202012408UA (en)
WO (1) WO2017217347A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985985A1 (en) * 2015-05-20 2016-11-24 Kagoshima University Specific modification of antibody by igg-binding peptide
KR20200002858A (en) * 2017-04-28 2020-01-08 아지노모토 가부시키가이샤 Compounds having affinity, cleavable moieties and reactive groups for soluble proteins or salts thereof
US11472865B2 (en) * 2017-06-16 2022-10-18 Kagoshima University IgG-binding peptide, and specific modification of antibody with said peptide
KR20200143366A (en) 2018-04-16 2020-12-23 니혼 메디피직스 가부시키가이샤 Modified antibodies and radioactive metal labeled antibodies
EP3811978A4 (en) * 2018-06-14 2022-03-16 Ajinomoto Co., Inc. Substance having affinity for antibody, and compound or salt thereof having bioorthogonal functional group
CN112262152A (en) * 2018-06-14 2021-01-22 味之素株式会社 Compound having affinity substance, cleavable moiety and reactive group for antibody, or salt thereof
CN113227124A (en) * 2018-10-31 2021-08-06 味之素株式会社 Compound having affinity substance, cleavable moiety and reactive group for antibody, or salt thereof
WO2022080481A1 (en) 2020-10-16 2022-04-21 日本メジフィジックス株式会社 Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
CN110007019A (en) * 2019-03-29 2019-07-12 绿城农科检测技术有限公司 A kind of method that simultaneous quantitative detects three kinds of antibody contents in breast milk
JP7356677B2 (en) 2019-05-22 2023-10-05 学校法人東京薬科大学 complex
IL292133A (en) * 2019-10-18 2022-06-01 Nihon Mediphysics Co Ltd Ri-labeled humanized antibody
EP4047010A4 (en) * 2019-10-18 2024-01-10 Nihon Mediphysics Co Ltd Method for producing radioactive metal-labeled antibody
CA3196365A1 (en) 2020-10-22 2022-04-28 Tomoyuki Imai Method for producing radioactive zirconium complex
CN116711028A (en) 2021-01-08 2023-09-05 日本医事物理股份有限公司 Method for producing Ac-225 solution and method for producing medicine using Ac-225 solution
WO2022196675A1 (en) 2021-03-16 2022-09-22 味の素株式会社 Complex or salt thereof, and method for manufacturing same
JPWO2022211051A1 (en) 2021-03-31 2022-10-06
EP4327831A1 (en) 2021-04-20 2024-02-28 Nihon Medi-Physics Co., Ltd. Radioactive complex of anti-cd20 antibody, and radiopharmaceutical
CN117377501A (en) 2021-04-21 2024-01-09 日本医事物理股份有限公司 Radioactive antineoplastic agent
WO2022225006A1 (en) 2021-04-21 2022-10-27 日本メジフィジックス株式会社 HUMANISED ANTIBODIES LABELLED WITH RADIONUCLIDES THAT EMIT β-RAYS
JPWO2023277144A1 (en) * 2021-06-30 2023-01-05
TW202325343A (en) 2021-08-31 2023-07-01 日商日本醫事物理股份有限公司 Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product
WO2023038082A1 (en) 2021-09-08 2023-03-16 国立大学法人 鹿児島大学 Compound, salt of compound, antibody modification reagent, method for producing modified antibody, and modified antibody
WO2023171809A1 (en) * 2022-03-11 2023-09-14 日本メジフィジックス株式会社 Method for producing fc-containing molecule modifying reagent
WO2023190402A1 (en) * 2022-03-30 2023-10-05 日本メジフィジックス株式会社 Method for producing complex
CN117466980A (en) * 2023-11-02 2024-01-30 浙江普罗亭健康科技有限公司 Supported metal conjugate based on polypeptide chain skeleton and applied to metal antibody labeling and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604092B1 (en) * 1986-09-19 1990-04-13 Immunotech Sa IMMUNOREACTIVES FOR TARGETING ANIMAL CELLS FOR VISUALIZATION OR DESTRUCTION IN VIVO
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
DE69942148D1 (en) * 1998-06-22 2010-04-29 Immunomedics Inc USE OF BISPECIFIC ANTIBODIES IN DIAGNOSIS AND THERAPY
EP1757311B1 (en) * 1999-12-24 2009-02-11 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US7230085B2 (en) * 2001-11-28 2007-06-12 Immunomedics, Inc. Anti-DOTA antibody
DE60331827D1 (en) * 2002-05-29 2010-05-06 Immunomedics Inc COMPOSITIONS FOR THE RADIOIMMUN THERAPY OF BRAIN TUMORS
WO2008054030A1 (en) * 2006-11-02 2008-05-08 Kagoshima University IgG-BINDING PEPTIDE
JP5994068B2 (en) * 2011-08-24 2016-09-21 国立大学法人 鹿児島大学 IgG-binding peptide and method for detecting and purifying IgG thereby
CA2985985A1 (en) * 2015-05-20 2016-11-24 Kagoshima University Specific modification of antibody by igg-binding peptide

Also Published As

Publication number Publication date
CN109071606A (en) 2018-12-21
KR20230027320A (en) 2023-02-27
TW201802108A (en) 2018-01-16
SG10202012408UA (en) 2021-01-28
CA3026520A1 (en) 2017-12-21
JP7165366B2 (en) 2022-11-04
JP2022008678A (en) 2022-01-13
JPWO2017217347A1 (en) 2019-05-09
EP3470418A4 (en) 2019-12-11
EP3470418A1 (en) 2019-04-17
JP6959616B2 (en) 2021-11-02
US20200181196A1 (en) 2020-06-11
WO2017217347A1 (en) 2017-12-21
KR20190018423A (en) 2019-02-22

Similar Documents

Publication Publication Date Title
SG11201810923YA (en) SITE-SPECIFIC RADIOISOTOPE-LABELED ANTIBODY USING IgG-BINDING PEPTIDE
MX2022014867A (en) Antibodies specific to human poliovirus receptor (pvr).
CL2019002855A1 (en) Anti-ilt4 antibodies and antigen-binding fragments.
IL265330A (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
PT3458479T (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2017004026A8 (en) Anti-cd123 antibodies and conjugates and derivatives thereof
PH12019501014A1 (en) Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
SA517381703B1 (en) Anti-C10orf54 Antibodies And Uses Thereof
IL266885A (en) Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
MY192822A (en) An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use
CR20170383A (en) ANTI-CD3 ANTIBODIES, ANTI-CD-123 ANTIBODIES AND BIESPECIFIC ANTIBODIES THAT SPECIFICALLY JOIN CD3 AND / OR CD123
SG11202103670XA (en) Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
MA38797A1 (en) Therapeutic fusion protein
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
MX2019002968A (en) Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer.
SG11202009990UA (en) Modified antibody and radioactive metal-labelled antibody
SA518391121B1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
ZA202105150B (en) Conjugate comprising ligand and ceacam5 antibody fab fragment
IL275765A (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
IL277575A (en) Antibodies for chelated radionuclides
EA201991673A1 (en) LAB3-labeled RADIOACTIVE ISOTOPE ANTIBODIES FOR IMMUNO-PET VISUALIZATION
GB2548653A (en) Immunoassay utilizing trapping conjugate
SG11202011232VA (en) Anti-cd63 antibodies, conjugates, and uses thereof
CR20220061A (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX2015010145A (en) Immuno imaging agent for use with antibody-drug conjugate therapy.